Debnath Souvik, Karan Saumen, Debnath Manish, Dash Jyotirmayee, Chatterjee Tapan Kumar
Pharmacology Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Jadavpur, India. Email:
Asian Pac J Cancer Prev. 2017 Aug 27;18(8):2255-2268. doi: 10.22034/APJCP.2017.18.8.2255.
Background: This study focuses on the role of Poly-L-lysine (PLL), an essential amino acid, on molecular changes of tumor angiogenesis suppression, pro-apoptotic and anti-apoptotic gene expression after treatment on Ehrlich ascites carcinoma (EAC) and solid sarcoma-180 tumor cells bearing mice. Materials and Methods: The cell viability was carried out using MTT assay. The antitumor activity was evaluated by treatment with PLL at 20 and 40mg/kg/b.w doses for 14 days in EAC ascites tumor and 21 days for Sarcoma-180 solid tumor model. Several tumor evaluation studies, haematological and biochemical parameters were estimated. Importantly, the tumor cell apoptosis was assessed using microscopic observations, DNA fragmentation assay, Flow cytometric analysis, cell-cycle and electron-microscopic study, following which, the expression of several signal proteins related to pro-apoptosis, anti-apoptosis and tumor angiogenesis were quantified using western blotting and immunohistochemistry study. Results: Precisely, PLL had cytotoxic effect on K562; A549; U937 and B16F10 cancer cells. Significant decreases in liquid and solid tumors and increased life span of treated mice were observed (P<0.05). Typical morphological changes, apoptosis bleb phenomenon and sub-G1 cell cycle arrests revealed that PLL promoted apoptotic cell death. Western blot and immunohistochemistry confirms, PLL activated apoptotic signalling cascades through down regulation of Bcl-2 and CD31 protein and upregulation of Bax and p53 proteins. The anti-angiogenic effects were also accompanied with decreased VEGF expression and reduced peritoneal-angiogenesis and microvessel density. Conclusions: The antitumor and antitumor-angiogenic activity of PLL was confirmed from all the results via up and down regulation of relevant signal proteins reported in this publication.
本研究聚焦于必需氨基酸聚-L-赖氨酸(PLL)对荷艾氏腹水癌(EAC)和实体肉瘤-180肿瘤细胞小鼠治疗后肿瘤血管生成抑制、促凋亡和抗凋亡基因表达的分子变化的作用。
采用MTT法检测细胞活力。通过以20和40mg/kg体重的剂量用PLL处理EAC腹水肿瘤14天以及肉瘤-180实体肿瘤模型21天来评估抗肿瘤活性。估计了几项肿瘤评估研究、血液学和生化参数。重要的是,通过显微镜观察、DNA片段化分析、流式细胞术分析、细胞周期和电子显微镜研究评估肿瘤细胞凋亡,随后,使用蛋白质印迹和免疫组织化学研究对几种与促凋亡、抗凋亡和肿瘤血管生成相关的信号蛋白的表达进行定量。
确切地说,PLL对K562、A549、U937和B16F10癌细胞具有细胞毒性作用。观察到液体和实体肿瘤显著减少,治疗小鼠的寿命延长(P<0.05)。典型的形态学变化、凋亡小泡现象和亚G1期细胞周期停滞表明PLL促进凋亡细胞死亡。蛋白质印迹和免疫组织化学证实,PLL通过下调Bcl-2和CD31蛋白以及上调Bax和p53蛋白激活凋亡信号级联反应。抗血管生成作用还伴随着VEGF表达降低以及腹膜血管生成和微血管密度降低。
通过本出版物中报道的相关信号蛋白的上调和下调,所有结果均证实了PLL的抗肿瘤和抗肿瘤血管生成活性。